calcipotriene


Also found in: Medical.
Related to calcipotriene: Calcitriol, Tazarotene, Calcipotriol
Translations

calcipotriene

n calcipotrieno
References in periodicals archive ?
Release date- 07082019 - Copenhagen - MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the completion of enrollment for its EU Phase 3 study assessing the safety and efficacy of MC2-01 PAD Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in adult patients with plaque psoriasis compared to Daivobet gel (marketed in the US as Taclonex Topical Suspension).
- The US Food and Drug Administration has expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older, US-based medical dermatology company Leo Pharma Inc., a wholly owned subsidiary of Denmark-based Leo Pharma A/S, said.
Yet another example of changing the vehicle to improve efficacy can be seen with the fixed-dose combination of calcipotriene and betamethasone dipropionate.
M2 EQUITYBITES-May 23, 2019-US Food and Drug Administration approves Mayne Pharma Group's SORILUX (calcipotriene) Foam
Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for SORILUX (calcipotriene) Foam, 0.005%, for treating plaque psoriasis of the scalp and body in patients aged 12 years and older.
Localized plaques that do not restrict movement may be treated with topical corticosteroids, calcipotriene, and tacrolimus.
In a randomised, double-blinded, controlled trial of Van der Vleuten CJ et al, [21] 71.2% of patients achieved "absent" or "very mild" disease with the two-compound scalp formulation, compared to 64% with betamethasone dipropionate and 36.8% with calcipotriene alone.
Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
Since our patient's underlying CML necessitated continued treatment with dasatinib and he declined procedural treatments, we treated his dyschromia topically with mometasone 0.1% and calcipotriene 0.005% creams.